Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medical & Biological Laboratories (MBL) has licensed Envoy Therapeutics to use its patented RIP-Chip technology, under an agreement signed between the two parties.
Subscribe to our email newsletter
The tie up allows Envoy to use MBL’s RIP-Chip technology for its drug discovery and development purpose.
Under the agreement, Envoy is responsible to pay an upfront payment, annual licensing fees and milestone payments to MBL.
MBL president Katsuhiko Nishida said this agreement provides Envoy a freedom-to-operate condition of our technology as well as a complementary approach to discover novel drug targets.
"RIP-Chip technology can provide additional information to their drug discovery pipelines regarding MOA and/or toxicological information of new drugs," Nishida said.